/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
-0.24%
Natural Gas
+2.22%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.11%
VIX
N/A
Economic Calendar
EUR/USD
-0.24%
Natural Gas
+2.22%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.11%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
The Market News Today: Upcoming PCE Report to Influence Fed’s Rate Decisions
about 3 hours ago
US GDP for Previous Quarter Adjusted Upward to a Robust Annual 3.4%
about 19 hours ago
The Market News Today: US GDP Forecast at 3.2%, Eyes on Fed and Market Response
about 22 hours ago
German Retail Sales Tumble 1.9% in February Driving ECB Rate Cut Bets
1 day ago
Georgia’s Credit Outlook Constrained By Geopolitical Sensitivities, Institutional Risks
2 days ago
Crude Oil Inventories Rise By 3.2 Million Barrels, Exceeding Analyst Expectations
2 days ago
Bitcoin Fails To Surpass $71k This Week
15 minutes ago
EUR/USD, GBP/USD, DXY Price Forecast: Good Friday Eyes on Fed Talks
about 3 hours ago
Gold, Silver, Copper Daily Forecast: Eyes on FED; More Buying Ahead?
about 4 hours ago
Natural Gas and Oil Forecast: Middle East Strife Spurs Rise; Buying Ahead?
about 5 hours ago
Bitcoin (BTC) News Today: No BTC-Spot ETF Market Dry Up Amidst ETH-Spot ETF Chatter
about 10 hours ago
XRP News Today: Ripple Case Update and Ongoing Investigation Sparks Investor Interest
about 8 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
SRPT
profile
Sarepta Therapeutics Inc
Follow
SRPT
(
Nasdaq - US
)
Closed
129.46
-0.77 (-0.59%)
in
:
usd
•
As of: Mar 28, 2024 15:59
UTC -4
Open
131.16
High
131.16
Low
127.86
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Sarepta Therapeutics Inc
CEO
Douglas S. Ingram
Headquarters
215 first street, suite 415
cambridge, ma 02142, united states
Auditor
KPMG LLP
Employees
1,314
Share Holders
157
Website
www.sarepta.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder affecting children. The company received accelerated approval for Exondys 51, Amondys 45 (casimersen) and Vyondys 53 (golodirsen). Exondys 51 is Sarepta's first PMO-based technology to be granted accelerated approval by the FDA. The company is conducting a confirmatory study on the clinical benefits of these drugs for gaining continued approval. The rest of its exon-skipping DMD pipeline includes a PPMO-based, exon 51 skipping candidate, SRP-5051. Sarepta is also developing gene therapies for treating DMD, Limb-girdle muscular dystrophy and central nervous system disorders including Mucopolysaccharidosis type IIIA and Pompe Disease.
Sarepta Therapeutics Inc
Statistics
Valuation Measures
Market Capitalization
2
12.16B
Enterprise Value
12.97B
Enterprise Value/EBITDA
(ttm)
-48.09
Price to Earnings Ratio
(ttm)
N/A
Price to Book
(mrq)
13.96
Price to Sales
(ttm)
9.69
Price to Cash
(ytd)
N/A
Profitability
Gross Margin
(ttm)
87.71%
Operating Margin
(ttm)
-11.74%
Profit Margin
(ttm)
-53.46%
Return on Equity
(ttm)
-18.97%
Return on Invested Capital
(ttm)
-27.51%
Return on Assets
(ttm)
-4.65%
Income Statement
Revenue
(ttm)
1.24B
Revenue Per Share
(ttm)
13.25
Gross Profit
(ttm)
1.09B
EBITDA
(ttm)
3
-269.60M
Net Income Avi to Common
(ttm)
-535.98M
Diluted EPS
(ttm)
-6.12
Share Statistics
Beta (5Y Monthly)
0.94
52-Week Change
-5.20%
S&P500 52-Week Change
30.45%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
93.86M
Dividend Yield
0.00%
Float
4
86.95M
%
Held by Insiders
7.40%
%
Held by Institutions
86.68%
Balance Sheet
Total Cash
(mrq)
1.68B
Total Cash Per Share
(mrq)
17.86
Total Debt
(mrq)
1.24B
Total Debt/Equity
(mrq)
144.06%
Current Ratio
(mrq)
3.95%
Quick Ratio
(mrq)
3.45%
Book Value Per Share
(mrq)
9.17
Cash Flow
Operating Cash Flow Per Share
(ytd)
-5.42
Free Cash Flow
(ytd)
-577.10M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker